Clinical trials for dementia

Before someone can take part in a clinical trial, there’s an important first step called the pre-screening stage. This is a simple process that helps the research team to see if you might be a good fit for the study. These questions may be asked via phone, online form, or during an initial clinic visit.

They might ask:

• Do you have a diagnosis of dementia or mild cognitive impairment?
• What other medications are you currently taking?
• Do you have someone, like a family member of a carer, who can act as your study partner?

Screening volunteers is important to make sure the trial is safe for the person taking part and that they meet the specific criteria needed for the study.

During the screening stage, researchers will ask questions about your health, lifestyle, and medical history. You might also be asked to attend a clinic visit for some health checks, such as

• blood tests
• memory assessments
• physical exams
• brain scans.

Not everyone who goes through screening will be suitable to take part in the trial.

Before someone agrees to take part in a clinical trial, research staff must describe it to the volunteer in detail. This includes any possible benefits and risks associated with the study.

If someone is happy to go ahead, they will be asked to sign a consent form stating that they understand what the trial involves and that they agree to take part.

Volunteers can still change their mind after signing this form. If someone does change their mind, they are free to withdraw at any time without giving a reason.

Once someone has passed the screening phase and is accepted into a clinical trial, they move on to the treatment or intervention stage. This is the part of the trial where the actual study treatment or intervention is given.

Depending on the type of trial, the treatment or intervention could be a new drug, a medical device, a lifestyle change like a diet or exercise programme, or even a combination of approaches.

Some people in the trial may receive the treatment being tested, while others may receive a dummy drug, or ‘placebo’ or the current standard treatment. This allows researchers to compare the effects between the volunteer groups.

This phase is carefully planned and monitored. Volunteers may visit a clinic regularly for health checks, memory or thinking tests, or to report any changes or side effects. This helps researchers understand how well the treatment works and whether it’s safe.

Every person’s experience is different, and not every treatment will lead to immediate benefits. But taking part in this phase is a powerful way to contribute to progress. The information gathered during the treatment phase is essential in the search for effective ways to treat, slow, or even prevent diseases like Alzheimer’s.

Marian was diagnosed with Alzheimer’s disease aged 69. Since then, Marian has taken part in three different drug trials with her husband, Geoff, supporting as her study partner. We asked them to share their experience of taking part in dementia research.

After the treatment or intervention phase of a clinical trial ends, participants move into the safety follow-up stage. This final stage is just as important as the earlier parts of the trial.

The purpose of the safety follow-up phase is to check how participants are doing after the treatment has stopped. Researchers want to make sure there are no unexpected side effects or long-term issues. This phase also helps them understand how lasting the effects of the treatment might be.

During this time, participants may be asked to return for check-up visits, answer questions about how they’re feeling, or have follow-up tests such as blood work, scans, or memory assessments. The length of the safety follow-up phase can vary depending on the type of treatment being studied.

Even though the treatment has ended, your involvement continues to play a key role. The information collected during the follow-up phase helps ensure the treatment is not only effective but also safe over time.

After the main part of a clinical trial ends, some studies offer volunteers the chance to join an open-label extension phase. This phase allows researchers to continue studying the treatment over a longer period and gives participants ongoing access to it.

In an open-label extension, everyone in the study knows what treatment they are receiving. This is different to the main study, where people don’t know whether they’re on the drug or placebo. Usually all participants are offered the treatment being tested, even if they were originally in a placebo group (dummy drug) during the main trial.

This phase is especially valuable in dementia research, where long-term safety and effects of a treatment are important to understand.

It helps researchers see how the treatment works overtime, whether it continues to be safe, and if it offers any lasting benefits.